Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component

Tim Goodnow, President and Chief Executive Officer of Senseonics

“Now being tested in humans for the first time, the Freedom CGM represents our vison to eliminate the requirement for an on-body component, effectively making continuous glucose monitoring invisible. We believe this represents an extremely attractive proposition for millions of people with diabetes and we are proudly leading the race to get there,”

Tim Goodnow, President and Chief Executive Officer of Senseonics

“At Senseonics, we are not interested in incremental innovation. Our mission is to transform lives in the diabetes community and push the boundaries of sensing technology to improve health and wellbeing. Eversense 365 redefined what a CGM could be by becoming the world's first and only one-year system and we are just getting started.”

Mukul Jain, Chief Operating Officer of Senseonics

“Freedom exemplifies our approach to innovation at Senseonics. We are focused on developing game-changing advances that simplify life with diabetes and help make diabetes technology less visible.”

Mukul Jain, Chief Operating Officer of Senseonics

“This R&D approach leverages validated technologies wherever possible to reduce risk and accelerate innovation. Supported by encouraging preclinical communication data, we are excited to begin evaluating Freedom in humans. This program is being driven by what we consistently hear from people living with diabetes and it is what Senseonics was founded to deliver – a one-year CGM sensor with nothing required on-body.”